NCT03710122View on ClinicalTrials.gov

Vancomycin for Primary Sclerosing Cholangitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 23, 2020

Primary Completion Date

March 3, 2025

Study Completion Date

March 20, 2025

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Vancomycin

Firvanq by Azurity Pharmaceuticals, Inc.

OTHER

Placebo

Placebo for Vancomycin

Trial Locations (4)

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic Rochester, Rochester

85259

Mayo Clinic Arizona, Phoenix

85281

Arizona State University, Tempe

All Listed Sponsors
collaborator

Arizona State University

OTHER

lead

Elizabeth Carey

OTHER

NCT03710122 - Vancomycin for Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter